Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study

被引:52
作者
D'Amico, D [1 ]
Solari, A
Usai, S
Santoro, P
Bernardoni, P
Frediani, F
Marco, R
Massetto, N
Bussone, G
机构
[1] Ist Nazl Neurol Carlo Besta, Milan, Italy
[2] S Gerardo Hosp, Dept Neurol, Monza, Italy
[3] Serv Neurol, Pieve Di Coriano, Italy
[4] Policlin S Pietro, Dept Neurol, Ponte San Pietro, Italy
[5] Osped Riuniti Bergamo, Dept Neurol, I-24100 Bergamo, Italy
[6] S Paolo Hosp, Dept Neurol, Milan, Italy
关键词
migraine; prophylaxis; activity limitations; health-related quality of life (HRQoL); migraine disability assessment score (MIDAS); short form 36 (SF-36);
D O I
10.1111/j.1468-2982.2005.01094.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Improved health-related quality of life (HRQOL) and reduced activity limitations are prime objectives of migraine therapy, but no data on the effect of preventive treatments on these outcomes are available. We monitored changes in HRQOL using the Short Form 36 (SF-36) and headache-related activity limitations using the Migraine Disability Assessment Score (MIDAS) in 141 consecutive migraine without aura patients on prophylaxis. A total of 102 patients completed the 3-month study. Mean (SD) number of headache days/month dropped from 8.0 (3.7) to 5.0 (2.3) (P < 0.001). Mean monthly consumption of acute drugs reduced from 7.4 (3.5) to 4.4 (3.1) (P < 0.001). MIDAS total score reduced (improved) significantly. All SF-36 scale scores increased (improved), most significantly. This first study to assess prospectively the impact of prophylaxis on HRQOL and daily activities in a large series indicates that migraine prophylaxis has the potential to reduce the global burden of migraine on individuals and society.
引用
收藏
页码:691 / 696
页数:6
相关论文
共 33 条
[1]
The Italian SF-36 Health Survey: Translation, validation and norming [J].
Apolone, G ;
Mosconi, P .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1025-1036
[2]
THE POWERFUL PLACEBO [J].
BEECHER, HK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1955, 159 (17) :1602-1606
[3]
Restoring migraine sufferers' ability to function normally: A comparison of rizatriptan and other triptans in randomized trials [J].
Bussone, G ;
D'Amico, D ;
McCarroll, KA ;
Gerth, W ;
Lines, CR .
EUROPEAN NEUROLOGY, 2002, 48 (03) :172-177
[4]
The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version [J].
D'Amico, D ;
Mosconi, P ;
Genco, S ;
Usai, S ;
Prudenzano, AMP ;
Grazzi, L ;
Leone, M ;
Puca, FM ;
Bussone, G .
CEPHALALGIA, 2001, 21 (10) :947-952
[5]
Workplace disability in migraine: an Italian experience [J].
D'Amico, D ;
Genco, S ;
Perini, F .
NEUROLOGICAL SCIENCES, 2004, 25 (Suppl 3) :S251-S252
[6]
D'Amico D, 2004, HEADACHE CARE, V1, P123
[7]
Dahlof C, 2004, CEPHALALGIA, V24, P808
[8]
DAHLOF C, 1989, NEW ADV HEADACHE RES, P281
[9]
Work and productivity loss in the rizatriptan multiple attack study [J].
Dasbach, EJ ;
Carides, GW ;
Gerth, WC ;
Santanello, NC ;
Pigeon, JG ;
Kramer, MS .
CEPHALALGIA, 2000, 20 (09) :830-834
[10]
Validation of a migraine work and productivity loss questionnaire for use in migraine studies [J].
Davies, GM ;
Santanello, N ;
Gerth, W ;
Lerner, D ;
Block, GA .
CEPHALALGIA, 1999, 19 (05) :497-502